MORRISTOWN, N.J.

莫里斯敦，新泽西州

,

，

May 13, 2026

2026年5月13日

/PRNewswire/ -- Whitehawk Therapeutics, Inc. (the 'Company' or 'Whitehawk') (Nasdaq:

/PRNewswire/ -- 白鹰治疗公司（Whitehawk Therapeutics, Inc.）（“公司”或“白鹰”）(纳斯达克:

WHWK

WHWK

), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced that it has entered into a securities purchase agreement with certain qualified institutional buyers and accredited investors for a private investment in public equity ('PIPE') financing that is expected to result in gross proceeds of approximately $87.5 million, before deducting placement agent fees and other private placement expenses..

），一家临床阶段的肿瘤治疗公司，运用先进技术于已知的肿瘤生物学以高效提供改良的抗体药物偶联物（ADC）癌症治疗方案，今天宣布已与某些合格的机构买家和认证投资者签订了一份证券购买协议，进行一项私募股权投资（PIPE）融资，预计将带来约8750万美元的总收益，在扣除配售代理费用和其他私募相关开支之前。

The PIPE financing includes participation from existing investors including Avoro Capital, QVT, Coastlands Capital, KVP Capital, ADAR1 Capital Management, Acuta Capital Partners, StemPoint Capital LP, Invus, as well as members of the Company's executive team.

PIPE 融资包括现有投资者的参与，这些投资者包括 Avoro Capital、QVT、Coastlands Capital、KVP Capital、ADAR1 Capital Management、Acuta Capital Partners、StemPoint Capital LP、Invus，以及公司执行团队的成员。

Pursuant to the terms of the securities purchase agreement, Whitehawk is selling an aggregate of (i) 4,330,866 shares of its common stock ('Common Stock') at a purchase price of $3.92 per share, and (ii) pre-funded warrants ('Pre-Funded Warrants') to purchase 17,991,021 shares of common stock at a purchase price of $3.9199 per Pre-Funded Warrant.

根据证券购买协议的条款，Whitehawk 正在出售总计 (i) 4,330,866 股普通股（“普通股”），每股购买价格为 3.92 美元，以及 (ii) 预先注资的认股权证（“预先注资认股权证”），用于购买 17,991,021 股普通股，每个预先注资认股权证的购买价格为 3.9199 美元。

The Pre-Funded Warrants have an exercise price of $0.0001 per share. The PIPE financing is expected to close on May 14, 2026, subject to the satisfaction of customary closing conditions..

预融资认股权证的行权价格为每股 0.0001 美元。PIPE 融资预计将于 2026 年 5 月 14 日完成，但需满足惯例交割条件。

Whitehawk intends to use the net proceeds from the PIPE financing, together with its existing cash, cash equivalents and marketable securities, for working capital and general corporate purposes, including advancing its ADC pipeline and related development activities. Proceeds from the PIPE financing, together with the Company's existing cash, cash equivalents and marketable securities, is expected to extend the Company's cash runway into the second half of 2028..

Whitehawk 打算将此次 PIPE 融资的净收益与其现有的现金、现金等价物和可出售证券一起用于营运资金和一般公司用途，包括推进其 ADC 管线及相关开发活动。PIPE 融资的收益与公司现有的现金、现金等价物和可出售证券相结合，预计将使公司的现金储备延长至 2028 年下半年。

Jefferies and Leerink Partners are acting as lead placement agents for the PIPE financing. Oppenheimer & Co., Citizens Capital Markets and Jones are also acting as placement agents for the PIPE financing.

Jefferies和Leerink Partners担任PIPE融资的主要配售代理。Oppenheimer & Co.、Citizens Capital Markets和Jones也担任PIPE融资的配售代理。

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor a solicitation of any vote or approval with respect to the proposed transactions or otherwise, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction..

本新闻稿不构成出售这些证券的要约或购买这些证券的要约邀请，也不构成与拟议交易或其他事项有关的任何投票或批准的邀请，且在根据任何州或其他司法管辖区的证券法进行注册或资格认证之前，在该州或其他司法管辖区进行此类要约、邀请或销售属非法行为的情况下，不得在任何州或其他司法管辖区出售这些证券。

The offer and sale of securities of Whitehawk described above are being made in a transaction not involving a public offering and the securities have not been registered under the Securities Act of 1933, as amended (the 'Securities Act'), or any state or other applicable jurisdiction's securities laws and may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and/or applicable state or other jurisdictions' securities laws..

上述Whitehawk证券的要约和销售是在不涉及公开发售的交易中进行的，这些证券尚未根据经修订的《1933年证券法》（“证券法”）或任何州或其他适用司法管辖区的证券法注册，并且除非依据有效的注册声明或适用的证券法及/或适用州或其他司法管辖区证券法的注册要求豁免，不得在美国重新要约或转售。

About Whitehawk Therapeutics

关于白鹰治疗公司

Whitehawk Therapeutics is a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Whitehawk's advanced three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.

白鹰治疗公司是一家临床阶段的肿瘤治疗公司，运用先进技术于已确立的肿瘤生物学，以高效提供改良的癌症治疗方法。白鹰先进的三资产ADC产品组合旨在克服第一代前辈的局限性，为难治性癌症患者带来有意义的影响。

These assets are in-licensed from WuXi Biologics under an exclusive development and global commercialization agreement..

这些资产是根据独家开发和全球商业化协议从药明生物获得许可的。

Forward Looking Statements

前瞻性声明

The Company cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. Such forward-looking include, but are not limited to the expected closing date, gross proceeds of the PIPE financing, the Company's cash runway with the proceeds from this PIPE financing and with existing cash, cash equivalents and marketable securities, the anticipated use of proceeds of the PIPE financing, and the registration for resale of the securities being issued and sold in the PIPE financing.

公司提醒您，本新闻稿中包含的关于非历史事实的陈述为前瞻性陈述。这些前瞻性陈述包括但不限于预计的成交日期、PIPE融资的总收益、公司通过此次PIPE融资所得款项以及现有现金、现金等价物和可出售证券的现金跑道、PIPE融资所得款项的预期用途，以及在PIPE融资中发行和出售的证券的转售登记。

These statements are based on the Company's current beliefs and expectations. The inclusion of forward-looking statements should not be regarded as a representation by the Company that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in the Company's business, including, without limitation, market, market risks and other market conditions; the risk that the conditions to the closing of the PIPE financing are not satisfied; potential delays in the commencement, enrollment and completion of clinical trials; disruption to the Company's operations from the ongoing geopolitical military conflicts around the world; the Company's dependence on third parties in connection with product candidate manufacturing, research and preclinical and clinical testing; disruptions in the supply chain, including raw materials needed for manufacturing and animals used in research; delays in site activations and enrollment of clinical trials; the results of preclinical studies; early clinical trials not necessarily being predictive of future results; the success of the Company's clinical trials and preclinical studies for its product candidates; inte.

这些声明基于公司当前的信念和期望。包含前瞻性声明不应被视为公司对其任何计划将会实现的承诺。由于公司业务中固有的风险和不确定性，实际结果可能与本新闻稿中所述的内容有所不同，这些风险和不确定性包括但不限于市场、市场风险及其他市场状况；私募股权投资（PIPE）融资完成条件未满足的风险；临床试验启动、招募和完成可能出现的延迟；全球持续的地缘政治军事冲突对公司运营的干扰；公司在产品候选制造、研究及临床前和临床测试方面对第三方的依赖；供应链中断，包括制造所需的原材料和用于研究的动物；临床试验地点激活和患者招募的延迟；临床前研究的结果；早期临床试验不一定能预测未来结果；公司产品候选的临床试验和临床前研究的成功与否；以及整合相关风险。

Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included in the Company's prior press releases and  Annual Report on Form 10-K for the fiscal year ended December 31, 2025, including under the caption 'Item 1A.

可能导致实际结果与前瞻性声明中预期的结果存在重大差异的其他风险和不确定性，已包含在公司之前的新闻稿和截至2025年12月31日财年的Form 10-K年度报告中，特别是在“第1A项”标题下。

Risk Factors,' filed on March 12, 2026, and in Whitehawk's subsequent Quarterly Reports on Form 10-Q, and elsewhere in Whitehawk's reports and other documents that Whitehawk has filed, or will file, with the SEC from time to time and that are available at .

风险因素”于2026年3月12日提交，并在Whitehawk随后的10-Q表季度报告中，以及Whitehawk已提交或将在未来不时提交给SEC的其他报告和文件中有所提及，这些文件可在以下位置查阅：。

www.sec.gov

www.sec.gov

.

。

All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Whitehawk undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

本新闻稿中的所有前瞻性陈述均仅在本日期有效，且除非适用法律要求，Whitehawk不承担修订或更新任何前瞻性陈述的义务，也不因新信息、未来事件或其他原因而作出任何其他前瞻性陈述。

All forward-looking statements are qualified in their entirety by this cautionary statement. This cautionary statement is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995..

所有前瞻性声明均受此警示声明的全面约束。此警示声明是根据1995年《私人证券诉讼改革法案》的安全港条款作出的。

Contact:

联系人：

[email protected]

电子邮件地址

SOURCE Whitehawk Therapeutics, Inc.

白鹰治疗公司

21

21

%

%

more press release views with

更多新闻发布视图

Request a Demo

请求演示